What Core Documents Are Required for UAE MOHAP Medical Device Registration?

Answer: The core documents for UAE MOHAP (Ministry of Health and Prevention) medical device registration include the product technical file (such as ISO 13485 quality management system certificate, CE or other recognized country certification), product description, intended use, risk analysis report, clinical evaluation report (if applicable), labels and instructions for use (in Arabic or English), manufacturing information, and authorized representative information. For high-risk devices such as implants and active devices, clinical trial data or equivalence comparison evidence may also be required. All documents must be submitted by the registrant, either a domestic manufacturer or a foreign manufacturer through a UAE local representative, to MOHAP's medical product registration system. The key step is to first determine the product classification under MOHAP classification rules, then prepare the corresponding technical file. Usually, Class II and above devices require more detailed clinical data. Ensure that the documents comply with the latest MOHAP guidance, such as MD-REG-001, and that all foreign-language documents are accompanied by notarized translations.

Source note: Compiled from Aimeili registration practice references, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product dossier.

Published: 2026-07-08 09:00 | Updated: 2026-07-08 09:00

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documents and Evidence
• Common Errors
• Company Preparation Checklist
• Aimeili's View
• Frequently Follow-up Questions
• Further Reading
• Applicable Boundaries

Key Summary

The core documents for UAE MOHAP medical device registration include the product technical file, such as ISO 13485 quality management system certificate, CE or other recognized country certification, product description, intended use, risk analysis report, clinical evaluation report if applicable, labels and instructions for use in Arabic or English, manufacturing information, and authorized representative information. For high-risk devices such as implants and active devices, clinical trial data or equivalence comparison evidence may also be required. All documents must be submitted by the registrant, either a domestic manufacturer or a foreign manufacturer through a UAE local representative, to MOHAP's medical product registration system.

The key step is to first determine the product classification under MOHAP classification rules, then prepare the corresponding technical file. Usually, Class II and above devices require more detailed clinical data. Ensure that the documents comply with the latest MOHAP guidance, such as MD-REG-001, and that all foreign-language documents are accompanied by notarized translations.

Applicable Scenarios and Core Questions

Companies searching for what core documents are required for UAE MOHAP medical device registration usually want to determine whether their existing documents can support a UAE submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member countries or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not sufficient. A more valuable approach is to first create reusable versions of the core technical file, quality management system evidence, performance verification, clinical evidence, labels, and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes. Then they can determine the risk class and submission pathway. If the pathway is incorrectly identified, subsequent translation, notarization, authorization, testing, and supplementary documents will all deviate from the correct direction.

For a UAE project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in commercial contracts, market control may be affected later.

Core Documents and Evidence

• Quality management system certificate: Copy of ISO 13485 or an equivalent system certification, such as MDSAP.
• Product technical file: Including design description, labels, and instructions for use, with at least an Arabic summary or full translation.
• Risk analysis report: Compliant with ISO 14971 or an equivalent standard.
• Clinical evaluation report: For Class IIb and Class III devices, provide a CE clinical evaluation report or equivalent documentation.
• Certificate of Free Sale: Issued by the regulatory authority of the country of origin, notarized and attested by the UAE embassy or consulate abroad.
• Authorized representative agreement: A legal agreement between the manufacturer and the UAE local representative.

Common Errors

• Submitting translated NMPA documents directly without rearranging the evidence according to the UAE pathway.
• Listing too many models or specifications while test reports, clinical evidence, or label coverage are insufficient.
• Choosing a local agent only based on sales cooperation, without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance duties.
• Inconsistencies among labels, instructions for use, promotional materials, and registration dossier claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and increased cost and timelines.

Company Preparation Checklist

• Confirm the product classification and communicate preliminarily with MOHAP.
• Appoint a UAE local representative, which may be a trading company or a registration agent.
• Organize the technical file and translate relevant content, with at least the summary and labels in Arabic.
• Obtain an ISO 13485 certificate that covers the product scope.
• If applicable, prepare clinical trial ethics committee approval documents.
• Pay the registration fee: approximately AED 1,500 for Class I and approximately AED 5,000 to AED 15,000 for Class II and above.

Aimeili's View

Aimeili recommends that companies not treat UAE registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix and then converting it according to each country's requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing supplementary documents country by country on an ad hoc basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the document evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the dossier appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Frequently Follow-up Questions

Can domestic documents be used directly for UAE registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in registration communication, certificate maintenance, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Further Reading

• Previous: Can CE Data Be Reused for Singapore HSA Medical Device Registration?
• Next: Why Is Brazil ANVISA Medical Device Registration So Long?

Recommended reading:

• What Should Companies Prepare Before Australia TGA Medical Device Registration?
• Can CE Data Be Reused for Singapore HSA Medical Device Registration?
• Why Is Brazil ANVISA Medical Device Registration So Long?
• What Is the Difference Between Vietnam Medical Device Import License and Registration Certificate?
• How to Choose a Local Agent for Indonesia Medical Device Registration?
• Will Thailand TFDA Medical Device Registration Be Returned If Documents Are Incomplete?

Return to FAQ Center | News | Contact Aimeili

Content Review and Applicable Boundaries

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicable boundaries: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements, testing conclusions, or legal opinions of the target country's regulatory authority.